cefquinome, an Innovative ß-lactam antimicrobial, is the 4th generation cephalosporin with antimicrobial activity against a broad spectrum of Gran-possive and Gram-nagative bacterial species and is the first 4^th generation cephalosporin approved for animal use. It has the following Characters: faster penetration of outer cell membrane (gram-negatives); lower affinity to ß-lactamases; higher affinity to target penicillin binding proteins.

For the treatment of clinical mastitis in lactating cows caused by Staphylococcus aureus, Stretococcus uberis, Stretococcus dysgalactiae, Escherichia coli  and other enterobacteria susceptible to cefquinome.In vitro, Cefquinome has antibacterial activity against common Gram negative and Gram positive bacteria including Salmonella spp. Haemophilus spp., Pasteurella spp., Klebsiella spp., Corynebaterium pyogenes, Escherichia coli, A. pleuropneumoniae, Proteus mirabilis, Staphylococcus aureus, Streptococcus dysgalactiae  and Streptococcus uberis.

  This drug also has the following merits:

  1. The first 4th generation cephalosporin approved for animal use

  2. broad-spectrum, the most excellent antibiotics for animal purpose